Evidence map›Paper›PMID 41898816›Full record

ReviewGenes2026

Precision Is Not Enough: When Tools Outpace Translation in Ocular Gene Therapy.

Maram E A Abdalla Elsayed, Robert E MacLaren

Abstract readReview
In one paragraph

Review in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maram E A Abdalla ElsayedNuffield Department of Clinical Neuroscience, University of Oxford, Oxford OX3 9DU, UK.
Robert E MacLarenNuffield Department of Clinical Neuroscience, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0002-3096-4682

Funding

Foundation Fighting Blindness Clinical Research FellowshipOxford NIHR Biomedical Research Centre, UK Department of Health
6 · The paper itself

Abstract

Advances in molecular biology have positioned the eye as a leading platform for gene therapy, owing to its surgical accessibility, relative immune privilege, and the ability of the contralateral eye to serve as an anatomical control. We trace the historical evolution of gene discovery, synthesize current gene therapy strategies for inherited and acquired ocular disorders, critically evaluating the limitations of CRISPR and related genome-editing technologies, and examine the key scientific and translational challenges that must be addressed for genetic therapies to be integrated into routine ophthalmic practice.

Indexed as

Eye DiseasesGene EditingGenetic TherapyAnimalsCRISPR-Cas SystemsHumansAAVbase editingclinical trialsCRISPRCRISPR/Cas9Gene editingocular gene therapyprime editingtranslationvector

Identifiers

PMID41898816
PMCPMC13026294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.